This week’s clinical AI milestones reveal a structural fault line: the capability to transform global healthcare now exists, but the market will not deploy it where the need is greatest.
The January 2026 launches of ChatGPT Health and Claude for Healthcare represent both tremendous promise and serious peril for the future of AI in medicine.
Nobel laureate David Baker’s team develops AI breakthrough for targeting ‘undruggable’ intrinsically disordered proteins, opening paths to treat cancers, neurodegenerative disorders, and metabolic conditions. Despite technological promise, implementation raises critical questions about AI diagnostic reliability and healthcare trust.
